Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GGKEV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
NBE-002
|
|||||
| Synonyms |
NBE 002; PNU-159682-anti-ROR1 antibody drug conjugate
Click to Show/Hide
|
|||||
| Organization |
NBE-Therapeutics AG
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 4 Indication(s)
Triple negative breast cancer [ICD11:2C60-2C65]
Phase 2
Lung cancer [ICD11:2C25]
Phase 1
Ovarian cancer [ICD11:2C73]
Phase 1
Multiple myeloma [ICD11:2A83]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
3.7-3.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-ROR1 mAb huXBR1-402
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
PNU-159682
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
LPETG-Gly5-EDA
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the Sortase A at the C-terminal of heavy and light chain.
|
|||||
| Combination Type |
Gly5-EDA-PNU
|
|||||
| DrugMap ID | ||||||
| TTD ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.